NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced enrollment of 40 patients and commencement of its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum. The study is being conducted by Renger Witkamp, Professor and Chair in Nutrition and Pharmacology, at Wageningen University in the Netherlands.
Selected from a pool of over 400 patients, 40 trial patients aged 18-65 will be subject to a randomized, double-blind, cross-over trial of 8 weeks. Patients will receive a maximum 6 chewing gums per day, either containing 50 mg of cannabidiol per chewing gum in case of the CanChew chewing gum, or a placebo chewing gum.
Final data collection for primary outcome measure is estimated to complete in April 2017, with the full
... read more at: https://globenewswire.com/news-release/2017/03/07/932877/0/en/AXIM-Biotech-Announces-Enrolled-Patients-Begin-Phase-II-Trial-for-the-Treatment-of-Irritable-Bowel-Syndrome-With-CanChew-Plus-Cannabidiol-CBD-Chewing-Gum.html